Colin Rowlings

Colin Rowlings is an accomplished pharmaceutical sciences executive with extensive experience in CMC (Chemistry, Manufacturing, and Controls) and product development. Currently serving as Senior Vice President of CMC at Actio Biosciences, Inc. since August 2024, Colin previously held senior leadership roles at Gossamer Bio, where responsibilities included overseeing CMC operations, and Ardea Biosciences, where Colin advanced multiple new chemical entities into clinical development. Colin's career also includes consulting work focused on formulation development and regulatory strategy, as well as key positions at Middlebrook Pharmaceuticals, Agouron, Rhone-Poulenc Rorer, and Eli Lilly and Co. Colin holds a Ph.D. in Pharmaceutics from the University of Iowa and a Bachelor of Pharmacy from The University of Queensland.